⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ORIC News
Oric Pharmaceuticals, Inc. Common Stock
Global Fusion Biopsy Market to Register Sustainable Growth at a CAGR of ~6% by 2034 | DelveInsight
globenewswire.com
BSX
CAH
MDT
GEHC
XRAY
AMGN
AZN
BMY
LLY
MRK
PFE
SNY
TEVA
JNJ
BIIB
GILD
NVS
GOOG
MSFT
IBM
NVDA
INTC
AMD
QCOM
AMAT
MU
NXPI
ASML
ADI
LRCX
KLAC
CDNS
SNPS
MCHP
ON
STM
MRVL
AEHR
TER
PAYX
CTAS
WST
ZBRA
VRSN
NOW
CRM
ADBE
PANW
CSCO
ACN
HPQ
ORCL
SAP
PTC
ALGN
ESTC
DDOG
SMCI
EXAS
CRSP
EDIT
BEAM
NTLA
REGN
VRTX
XOM
CVX
SHEL
BABA
JD
PDD
NTES
BIDU
IQ
BILI
VIPS
HTHT
EDU
TAL
MELI
AMZN
NFLX
DIS
CMCSA
VZ
T
SIRI
GOOGL
AAPL
META
TSLA
GE
PHI
BRKR
AUR
FONR
BFLY
CRI
EXEL
TAK
ABSI
JHG
XNCR
MOD
ARVN
CLAR
BNTX
FOR
ORIC
COOK
OWL
MTA
SKIN
HYPR
ALLT
MAGN
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
ORIC
Form 8-K
sec.gov
ORIC
ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
globenewswire.com
ORIC
Form 8-K
sec.gov
ORIC
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
globenewswire.com
ORIC
ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer
globenewswire.com
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
ORIC
Form 8-K
sec.gov
ORIC
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight
globenewswire.com
NVS
TLX
PFE
EXEL
LLY
XNCR
BTE
ORIC
MRK
ABBV
BMY
AZN
AMGN